- Featured Product
- KD/KO Validated
HDAC7 Polyclonal antibody
HDAC7 Polyclonal Antibody for IP, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, rat
Applications
WB, IP, ELISA
Conjugate
Unconjugated
Cat no : 26207-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive IP detected in | K-562 cells |
Recommended dilution
Application | Dilution |
---|---|
Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
KD/KO | See 1 publications below |
WB | See 4 publications below |
IP | See 1 publications below |
Product Information
The immunogen of 26207-1-AP is HDAC7 Fusion Protein expressed in E. coli.
Tested Reactivity | human, rat |
Cited Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | HDAC7 fusion protein Ag24396 |
Full Name | histone deacetylase 7 |
Calculated Molecular Weight | 103 kDa |
Observed Molecular Weight | 102 kDa |
GenBank Accession Number | BC006453 |
Gene Symbol | HDAC7 |
Gene ID (NCBI) | 51564 |
RRID | AB_2880426 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
Product Specific Protocols | |
---|---|
IP protocol for HDAC7 antibody 26207-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Int J Biol Sci Discovery of a novel HDACi structure that inhibits the proliferation of ovarian cancer cells in vivo and in vitro. | ||
J Exp Clin Cancer Res HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway.
| ||
Cell Death Dis AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway |